John James Laferla, MD | |
202 Coursevall Dr, Suite 107, Centreville, MD 21617-2804 | |
(410) 758-1250 | |
(443) 262-8001 |
Full Name | John James Laferla |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 202 Coursevall Dr, Centreville, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1851391288 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | D0057063 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
John James Laferla, MD 202 Coursevall Dr, Centreville, MD 21617-2804 Ph: () - | John James Laferla, MD 202 Coursevall Dr, Suite 107, Centreville, MD 21617-2804 Ph: (410) 758-1250 |
News Archive
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.
The Institute for Health and Productivity Management (IHPM) and i.e., LLC have joined to form MAGNETT Health, LLC using innovative engagement techniques and mobile health messaging technologies to inspire employees in improving and maintaining their health with achievable, lasting behavior change.
A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.
University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.
The study, published in the scientific journal Eurosurveillance, also counts on the participation of researchers from the Public Health Agency of Catalonia, the Lleida Institute of Biomedical Research and the Barcelona Public Health Agency.
› Verified 2 days ago